Pancreatic Cancer Research

ResearcherAmerican University of Beirut Medical CenterActive in the last 2 years

Sally Naji Temraz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8995-7946; OpenAlex author ID A5027939103, A5087290908. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Clinicopathological and Prognostic Implications of Epithelial-to-Mesenchymal Transition-Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A … Co-author DOI 10.1002/cnr2.70565↗
  2. Efficacy and Safety of Modified GTX as Second-Line Therapy in Advanced Pancreatic Adenocarcinoma: A Prospective Cohort Study. Last author DOI 10.1007/s12029-026-01504-z↗
  3. Pre-Operative Markers of Post-Operative Complications in Pancreatic Cancer Patients: A Single-Center Study. Co-author DOI 10.1007/s44197-025-00371-4↗
  4. Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a narrative review and case series. Co-author DOI 10.1111/ajco.13912↗
  5. Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1111/ajco.13775↗
  6. Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. Co-author DOI 10.1007/s12253-018-0464-y↗
  7. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-013-9571-x↗
  8. Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. Co-author PMID 23745160↗
  9. Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. Co-author PMID 23112885↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ali I. Shamseddine · 9 shared papers, 2012–2026 · strength 1.50
  2. Walid Ghazi Faraj · 4 shared papers, 2012–2026 · strength 0.45
  3. Laudy Chehade · 2 shared papers, 2023–2026 · strength 0.44
  4. Sara El Meski · 1 shared paper, 2026 · strength 0.36
  5. Ahmad Machmouchi · 1 shared paper, 2026 · strength 0.24
  6. Noura Abbas · 1 shared paper, 2026 · strength 0.24
  7. Ghassan K. Abou‐Alfa · 3 shared papers, 2012–2022 · strength 0.20
  8. Eileen Mary O'Reilly · 3 shared papers, 2012–2022 · strength 0.20
  9. Haifa Dbouk · 1 shared paper, 2022 · strength 0.14
  10. Fadi Farhat · 1 shared paper, 2022 · strength 0.14
  11. Samer Nassif · 1 shared paper, 2019 · strength 0.10
  12. Leonard B. Saltz · 2 shared papers, 2012–2013 · strength 0.06
  13. Hana Ajouz · 1 shared paper, 2014 · strength 0.04
  14. Elizabeth S. Won · 1 shared paper, 2013 · strength 0.03
  15. Kenneth H. Yu · 1 shared paper, 2013 · strength 0.03
  16. Alexandra Snyder Charen · 1 shared paper, 2012 · strength 0.03
  17. David Paul Kelsen · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.